

ADAP Medical Advisory Committee

April 19, 2023 Gathering Notes

1) Welcome and Rollcall

I. Welcome:

Gathering opened by Sharisse Kemp, ADAP Branch Chief

II. Introductions:

MAC Members, CDPH, and Magellan staff introduced themselves

MAC Members in Attendance

Stephen O'Brien, Lucas Hill, David Lewis, Cliff Okada, Joanna Eveland, Glenn San Agustin, Laveeza Bhatti, Arlet Arratoonian

CDPH/Office of AIDS staff in Attendance

Philip Peters, Sharisse Kemp, Becca Parks, James Vo, Alej Contreras, Linda Lewis

MAC Members not in Attendance

Wilbert Jordan, Michelle Sherman, Glenn San Agustin, Laveeza Bhatti, Danny Toub

Magellan Representatives in Attendance

Carrie Holden

2) ADAP / MAC Updates

I. Medications added to the ADAP formulary and updates:

- Podofilox and tinidazole sexually transmitted infection medications were added to the ADAP formulary.
- Beclomethasone nasal metered spray, Cefdinir, Cefpodoxime, and Cefuroxime sinusitis medications were added to the ADAP formulary.
- Empagliflozin (Jardiance®), Glipizide/Metformin, Glyburide (Glynase®, PresTab®, DiaBeta®), and Glimepiride (Amaryl®) diabetes medications were added to the ADAP formulary.
- Aripiprazole (Abilify Maintena®), Aripiprazole (Aristada®), Olanzapine (Zyprexa Relprevv™), Paliperidone (Invega Sustenna®), Risperidone (Risperdal Consta®) antipsychotic injectable medications were added to the ADAP formulary.
- Prior authorization has been removed from the following hepatitis C medications on the ADAP formulary: generic sofosbuvir-velpatasvir, generic ledipasvir/sofosbuvir and glecaprevir/pibrentasvir (Mavyret®).
- Insulin products and related supplies for diabetes are in the cost analysis process.
- Respiratory inhalers in the cost analysis process.
- Diabetes medications in the cost analysis process.

- II. Medications removed from the ADAP formulary:
 - The following HepC antivirals have been removed from the ADAP formulary as manufacturer discontinued production: Intron-A, Infergen, Roferon-A, Rebetol and Rebetron.
- III. Update on the medications discussed during the January's 2023 MAC gathering:
 - None

3) Medication Discussion

- I. Update: Lenacapavir (Sunlenca) is waiting for final departmental approval.
- II. No public comments.

4) PrEP-AP Formulary

- I. Buprenorphine-naloxone (Suboxone®), Buprenorphine (Subutex®), Naloxone Spray (Narcan®), injectable Naloxone, extended-release Naltrexone by intramuscular injection (Vivitrol®) and oral Naltrexone substance use disorder medications were added to the PrEP-AP formulary.

5) Opportunistic Infection Treatments

- I. Paxlovid is expected to receive U.S. Food and Drug Administration approval and will be evaluated for its addition to the ADAP formulary.

6) Magellan Rx Presentation

- I. Carrie Holden presented on:
 - Benign Prostatic Hyperplasia, Osteoporosis, and Bisphosphonates

7) Close of Meeting

- I. The next ADAP MAC gathering is scheduled for July 19, 2023, from 7:30 a.m. to 9:00 a.m.

8) Action Items

Action Items	Owners
Mass communication outreach to Magellan network pharmacies	Carrie Holden

Action Items	Owners
Walk through ADAP enrollment process, high level overview	James Vo